First Time Loading...
S

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990

Watchlist Manager
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Watchlist
Price: 168 HKD 9.16% Market Closed
Updated: Apr 29, 2024
Section:
 

Wall Street
Price Targets

Price Targets Summary
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd

Wall Street analysts forecast Sichuan Kelun-Biotech Biopharmaceutical Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is 182.14 HKD with a low forecast of 109.7 HKD and a high forecast of 220.5 HKD.

Lowest Forecast
Wall Street Target
109.7 HKD
35% Downside
Average Forecast
Wall Street Target
182.14 HKD
8% Upside
Highest Forecast
Wall Street Target
220.5 HKD
31% Upside
Lowest
Price Target
109.7 HKD
35% Downside
Average
Price Target
182.14 HKD
8% Upside
Highest
Price Target
220.5 HKD
31% Upside
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd Competitors:
Price Targets
ARGX
argenx SE
37% Upside
MRSN
Mersana Therapeutics Inc
133% Upside
EXAI
Exscientia PLC
119% Upside
BNTX
BioNTech SE
40% Upside
ARGX
argenx SE
37% Upside
MRSN
Mersana Therapeutics Inc
133% Upside
EXAI
Exscientia PLC
119% Upside
BNTX
BioNTech SE
40% Upside
CRIS
Curis Inc
53% Upside
BPMC
Blueprint Medicines Corp
7% Upside
GRTS
Gritstone bio Inc
588% Upside
BIOCON
Biocon Ltd
6% Downside

Revenue
Forecast

Revenue Estimate
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd

The compound annual growth rate of Sichuan Kelun-Biotech Biopharmaceutical Co Ltd's revenue for the next 4 years is 31%.

N/A
Past Growth
31%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Sichuan Kelun-Biotech Biopharmaceutical Co Ltd's stock price target?
Price Target
182.14 HKD

According to Wall Street analysts, the average 1-year price target for Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is 182.14 HKD with a low forecast of 109.7 HKD and a high forecast of 220.5 HKD.

What is Sichuan Kelun-Biotech Biopharmaceutical Co Ltd's Revenue forecast?
Projected CAGR
31%

The compound annual growth rate of Sichuan Kelun-Biotech Biopharmaceutical Co Ltd's revenue for the next 4 years is 31%.

ALPHA SPREAD
Join more than 132,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.